NCT04283513View on ClinicalTrials.gov

Treatment of Hemorrhagic Fever With Ribavirin

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2027

Conditions
Hemorrhagic Fever
Interventions
DRUG

Virazole

Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL

Trial Locations (1)

Unknown

Landstuhl Regional Medical Center, Landstuhl

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED